LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW

Liminatus Pharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$3.11+0.07 (+2.30%)

Close on Oct 19, 2026

Market cap: $150.52M
P/E (TTM): –
Dividend yield: –

Liminatus Pharma, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Research & Development	–	2.69
General & Administrative	2.97	0.64
Operating Expenses	2.97	3.33
Operating Income	-2.97	-3.33
Interest Expense	0.22	0.34
Interest & Investment Income	0.08	0.12
Other Non-Operating Income	-7.24	-0.22
Net Income incl. Noncontrolling Interests	-10	-3.55
Net Income	-10	-3.55
EPS (Basic)(per share)	-0.43	-0.20
EPS (Diluted)(per share)	-0.43	-0.20
Shares Outstanding (Basic, Weighted)(shares)	24	18
Shares Outstanding (Diluted, Weighted)(shares)	24	18

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 70.0%

Financial strength

Current ratio: 1.12
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 99.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 500.71
Dividend yield: –